查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1987130

人类胰岛素市场规模、份额、趋势和预测：按产品类型、分销管道、疾病类型和地区划分，2026-2034 年

Human Insulin Market Size, Share, Trends and Forecast by Product Type, Distribution Channel, Disease Type, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2025年全球人类胰岛素市场规模为543亿美元。展望未来，IMARC集团预测，2026年至2034年间，该市场将以5.42%的复合年增长率成长，到2034年达到872亿美元。目前，北美市场占据主导地位，预计到2025年将占据超过46.5%的市场。推动市场成长的主要因素包括糖尿病盛行率的上升、老年人口的成长、人类胰岛素生产技术的快速发展、广泛的研发活动以及政府的支持政策。

由于糖尿病盛行率不断上升、新型胰岛素的研发以及公共卫生意识的增强，人类胰岛素市场正稳定成长。糖尿病盛行率的上升归因于人口老化和久坐生活方式的盛行，导致对高效胰岛素治疗的需求日益增长。治疗技术的进步，特别是长效胰岛素类似物以及胰岛素笔和胰岛素帮浦给药系统的改进，提高了治疗效果和患者遵从性。此外，生物类似胰岛素产品的创新解决了耐久性问题，并改善了市场准入，尤其是在开发中国家。同时，政府主导的倡议和对医疗保健领域的投资推动了市场扩张，早期诊断和有效管理糖尿病进一步促进了市场发展。

在美国，糖尿病的高发病率和医疗保健产业的蓬勃发展确保了人类胰岛素市场的重要地位。胰岛素类似物和创新给药系统的研发正在满足多样化的需求，同时也努力控制价格，以求达到最佳平衡。此外，监管政策的调整、胰岛素价格控制以及以患者为中心的解决方案也在影响市场动态。美国市场正透过积极的研发活动实现进一步成长，这些活动促进了创新，并建立了全球糖尿病护理标准。例如，2024年4月，总部位于美国的Vertex Pharmaceuticals公司获得了TreeFrog Therapeutics公司C-Stem技术的独家许可，用于提高第1型糖尿病细胞疗法的生产效率。此次合作旨在扩大细胞生产规模，并满足第1型糖尿病患者尚未充分满足的重大需求。

人类胰岛素市场趋势

糖尿病发生率增加

人类胰岛素在糖尿病的治疗和管理中发挥着至关重要的作用。糖尿病是一种以血糖值升高为特征的慢性代谢性疾病。根据世界卫生组织（WHO）统计，全球糖尿病患者人数从1990年的2亿增加到2022年的8.3亿，凸显了对糖尿病管理技术和医疗保健解决方案日益增长的需求。人类胰岛素广泛应用于胰岛素替代疗法、个人化治疗、以及特定疾病的治疗。此外，越来越多的产品用于补充人体无法产生的胰岛素，从而控制血糖水平并预防高血糖，这推动了第1型糖尿病治疗市场的成长。口服胰岛素製剂有时也会被配製成口服形式，尤其是与胰岛素注射併用时，以增强人体对葡萄糖的利用能力。另外，胰岛素帮浦治疗产品的日益普及也促进了市场成长。胰岛素帮浦治疗能够模拟健康胰臟的基础胰岛素分泌，并全天持续供应胰岛素。此外，人类胰岛素在术前和重症监护环境中发挥至关重要的作用，可以防止血糖值波动，并降低手术併发症的风险。

人口老化的过程

人类胰岛素在维持老年糖尿病患者的理想血糖值方面发挥着至关重要的作用。报告显示，全球65岁及以上人口的比例已从1974年的5.5%增加到2024年的10.3%，预计到2074年将达到20.7%。这凸显了老年人口的成长以及对老龄化相关医疗保健服务日益增长的需求。人类胰岛素能够根据老年人的年龄、病历、肾功能和整体健康状况等因素，实现个人化治疗和精准的剂量调整，从而满足其个别需求。此外，人类胰岛素具有良好的安全性，已在糖尿病治疗中应用数十年，与一些新型治疗方法相比，对老年人的风险较低。与其他一些糖尿病治疗方法相比，人类胰岛素还能最大限度地降低老年人发生低血糖的风险。此外，人类胰岛素的给药方式多种多样，包括胰岛素笔、注射器和胰岛素帮浦。这使得医护人员能够根据老年人的需求和偏好选择最适合的胰岛素给药方式。

人类胰岛素生产快速进展

重组去氧核糖核酸（DNA）技术的引入消除了从动物中提取胰岛素的需求，确保了胰岛素供应的稳定可靠。这些因素对市场成长产生了正面影响。此外，连续生产流程的引入使得胰岛素能够在最短时间内高效生产，同时以最低成本应对市场需求的波动，进一步促进了市场成长。此外，生物製程技术的最新进展，例如发酵条件、培养基成分和细胞培养製程的最佳化，透过最大限度地提高最终产品品质并最大限度地降低生产成本，推动了市场发展。根据产业报告显示，圣保罗大学和伊利诺大学厄巴纳-香槟分校的研究人员培育出了世界上第一头能够在牛奶中生产人类胰岛素的基因改造牛。这项突破性进展有望显着缓解胰岛素短缺，减轻糖尿病患者的负担，甚至可能使一小群牛能够永续满足一个国家的胰岛素需求。此外，透过整合层析法、过滤和亲和分离等先进加工技术来提高胰岛素纯化的效率和效果的努力也在推动市场成长。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球人类胰岛素市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依产品类型划分

  • 製药
    • 市场区隔：按类型
      • 人类胰岛素类似物和生物相似药
        • 短效
        • 长效型
        • 预混合料
      • 人类胰岛素生技药品
        • 短效
        • 中间作用类型
        • 预混合料
  • 管理设备
    • 市场区隔：按类型
      • 笔
        • 可重复使用的笔
        • 免洗笔
      • 笔针
        • 标准笔针
        • 安全笔针
      • 注射器
      • 其他的

第七章 市场区隔：依分销通路划分

  • 零售药房
  • 医院药房
  • 线上零售商店
  • 其他的

第八章 市场区隔：依疾病类型划分

  • 1型糖尿病
  • 2型糖尿病

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章 价格指标

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company（BD）
    • Biocon
    • Eli Lilly and Company
    • Gulf Pharmaceutical Industries（Julphar）
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Groupe Sanofi
    • SEDICO Co.
    • Wockhardt Limited
    • Ypsomed AG
Product Code: SR112026A1950

The global human insulin market size was valued at USD 54.3 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 87.2 Billion by 2034, exhibiting a CAGR of 5.42% from 2026-2034. North America currently dominates the market, holding a market share of over 46.5% in 2025. The growing incidences of diabetes, rising geriatric population, rapid advancements in human insulin production, extensive research and development (R&D) activities, and the implementation of supportive government policies are some of the major factors propelling the market.

The human insulin market is growing steadily due to the increasing incidence of diabetes, the development of new insulin types, and the growing health consciousness in the populace. The rising incidences of diabetes result from the increasing number of people aging and adoption of inactive lifestyle, hence increasing need for efficient insulin therapies. Technological advancements in the treatment, namely long-acting insulin analogs and in the delivery systems via insulin pens and pumps have improved the treatment effect and patient compliance. Further, innovation in the biosimilar insulin products is resolving durability issues and improving market accessibility, mainly in the developing economies. In addition, market expansion through governmental initiatives and investments in healthcare further supports the market based on early diagnostics and effective management of diabetes.

In the United States, the size of the market for human insulin maintains prominence owing to high incidence of diabetes and a developed healthcare industry. The development of the insulin analogs as well as the innovative delivery systems serve the heterogeneous demand, whereas the attempts to control the price also pursue to strike an optimum balance. In addition, regulatory changes and initiatives to cap insulin costs, alongside a focus on patient-centric solutions, are shaping market dynamics. The U.S. market obtains further gains from robust research and development activities, catalyzing innovation and setting global standards for diabetes care. For instance, in April 2024, Vertex Pharmaceuticals, a U.S based company, secured an exclusive license for TreeFrog Therapeutics' C-Stem technology to enhance the production of cell therapies for type 1 diabetes. This collaboration aims to scale up cell manufacturing, addressing the significant unmet needs of T1D patients.

HUMAN INSULIN MARKET TRENDS:

The growing incidences of diabetes

Human insulin plays a vital role in the treatment and management of diabetes, a chronic metabolic disorder characterized by elevated blood sugar levels. According to the World Health Organization (WHO), The number of diabetics worldwide increased from 200 million in 1990 to 830 million in 2022, underscoring the increasing demand for management techniques and healthcare solutions. It is widely used in insulin replacement, individualized therapy, and the management of specific conditions. In addition, the increased use of products in the treatment of type 1 diabetes to supply insulin that the body cannot produce to control the amount of glucose circulating in the blood and to avoid hyperglycemia enhances the growth of the market. Additionally, it is prescribed to be taken orally, especially for enhancing the body's ability to use up glucose with the help of insulin shots. Apart from this, the rising product adoption in insulin pump therapy to deliver a continuous supply of insulin throughout the day, mimicking the basal insulin secretion of a healthy pancreas, is contributing to the market growth. Moreover, human insulin plays a critical role in preoperative and critical care settings to prevent glucose fluctuations and reduce the risks of surgical complications.

The rising geriatric population

Human insulin plays a vital role in maintaining the desired levels of glycose in elderly group patients suffering from diabetes. According to reports, the global share of people aged 65 and over has increased from 5.5% in 1974 to 10.3% in 2024, with projections reaching 20.7% by 2074, highlighting a rising geriatric population and a growing demand for age-related healthcare services. It allows for individualized therapy and precise dosage adjustments to meet the specific needs of aging individuals based on factors such as age, medical history, renal function, and overall health status. Furthermore, human insulin has a well-established safety profile and has been used for decades in the treatment of diabetes, making it less risky for the geriatric population compared to newer treatments. Additionally, it aids in minimizing the risk of hypoglycemia in the elderly population compared to certain other diabetes medications. Apart from this, human insulin can be administered through various methods, including insulin pens, syringes, and insulin pumps, which allows healthcare providers to choose the most appropriate insulin delivery method based on the needs and preferences of geriatric individuals.

Rapid advancements in human insulin production

The introduction of recombinant deoxyribonucleic acid (DNA) technology eliminates the need for animal-based insulin extraction and provides a consistent and reliable source of insulin; these positively influence market growth. In addition, the implementation of the continuous manufacturing process, which provides efficient and effective production of insulin that is constantly and uninterruptedly manufactured within the shortest time possible with less cost and ability to meet fluctuations in market demand is adding to the market growth. Additionally, the recent improvements in the bioprocessing technology, such as the optimization of the fermentation conditions, media formulation, and cell culture processes, which help in minimizing the cost of production while at the same time maximizing the quality of the final products, are fueling this market. According to industry reports, researchers from Universidade de Sao Paulo and the University of Illinois Urbana-Champaign have created the first transgenic cow that can produce human insulin in her milk. This groundbreaking advancement could significantly alleviate insulin shortages and reduce costs for diabetes patients, with the potential for a small herd to sustainably meet the insulin needs of an entire nation. Moreover, the integration of advanced processing techniques, such as chromatography, filtration, and affinity-based separations, to improve the efficiency and effectiveness of insulin purification is strengthening the market growth.

HUMAN INSULIN INDUSTRY SEGMENTATION:

Analysis by Product Type:

  • Drugs
    • Human Insulin Analogs and Biosimilars Rapid Acting Long Acting Premixed
    • Human Insulin Biologics Short Acting Intermediate Acting Premixed
  • Delivery Devices
    • Pens Reusable Pens Disposable Pens
    • Pen Needles Standard Pen Needles Safety Pen Needles
    • Syringes
    • Others
  • Human Insulin Analogs and Biosimilars
    • Rapid Acting
    • Long Acting
    • Premixed
  • Human Insulin Biologics
    • Short Acting
    • Intermediate Acting
    • Premixed
  • Pens
    • Reusable Pens
    • Disposable Pens
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles

Drugs are dominating the market growth as they have been extensively researched and proven to be effective in managing diabetes. Furthermore, their established market presence has created familiarity and confidence among prescribers, leading to their continued dominance. Apart from this, human insulin drugs are easier to obtain and more affordable than newer types of insulin in the market that are patented. These are easily available and affordable, attributing to their widespread use, particularly in parts with limited resources settings. Apart from this, they have also gained health authority clearances in different parts of the world, helping guarantee the quality and efficiency of human insulin drugs. However, human insulin drugs have been more accepted by patients with diabetes because of their long history of use and proven effectiveness.

Analysis by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores

Retail pharmacies lead the market with around 59.2% of market share in 2025. Retail pharmacies are located in strategic areas such as shopping centers, in different neighborhoods, and some areas within the blend of urban centers, which makes it easy for patients with diabetes to easily access their prescribed medications. Furthermore, they have numerous outlets with stores in cities, regions, and countries, making it easier for the patients to access a nearest retail store where they refill human insulin prescriptions regardless of the location. Additionally, a network of many retail pharmacies has existed with different insurance companies and other government healthcare schemes to ensure efficient reimbursement processes. In addition, they offer other facilities in addition to prescription dispensing, such as proper use of human insulin, injection techniques, monitoring of blood glucose levels, and lifestyle modification.

Analysis by Disease Type:

  • Type I Diabetes
  • Type II Diabetes

Type I diabetes leads the market with around 57.6% of market share in 2025. It holds the majority market share due to its versatility in the global market. In addition, patients with type 1 diabetes depend on insulin injections from the time of diagnosis up to the remaining part of their lifespan. This high requirements for human insulin make it mandatory to have a constant supply to counter the increasing demand of insulin replacement therapy. Furthermore, the lack of natural insulin production in type 1 diabetes has opened a very significant market demand as the primary source for insulin replacement. Besides this, human insulin maintains more accurate resemblance to the insulin demand of patients with type 1 diabetes compared to other insulin analogs because it is characterized and produced similarly to the natural insulin produced in the human body.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 46.5%. The region is dominating the market as it has a significant burden of diabetes, with both type 1 and type 2 diabetes being prevalent in the region. Furthermore, it boasts a well-developed healthcare infrastructure characterized by advanced medical facilities, research institutions, and pharmaceutical companies, which supports the production, distribution, and accessibility of human insulin. Additionally, North America is at the forefront of technological advancements in the healthcare sector, including the development of innovative insulin delivery systems, such as insulin pens and insulin pumps, which enhance the administration and effectiveness of human insulin. Moreover, the presence of several leading pharmaceutical companies that are actively engaged in the production and distribution of human insulin is acting as another growth-inducing factor. Apart from this, North America has well-established regulatory bodies which ensure the safety, efficacy, and quality of pharmaceutical products, including human insulin.

KEY REGIONAL TAKEAWAYS:

UNITED STATES HUMAN INSULIN MARKET ANALYSIS

In 2025, United States accounted for 88.50% of the market share in North America. The growing adoption of human insulin in the United States is largely driven by increasing investment in healthcare. For instance, U.S. health spending rose 4.1% in 2022 to USD 4.5 Trillion, benefiting human insulin development by boosting investment in healthcare innovation and accessibility. Significant investment is allocated to the healthcare industry with the goal of strengthening the infrastructure of medical treatment, including increasing the accessibility and availability of necessary drugs like insulin. With this surge in healthcare investments, there has been a marked improvement in healthcare accessibility, especially for chronic conditions such as diabetes. As a result, more individuals are gaining access to affordable and effective treatments, leading to higher adoption rates of human insulin. This trend is further supported by advancements in medical technologies, increasing awareness about diabetes management, and government initiatives to provide better healthcare services. Enhanced healthcare access allows patients to better manage their conditions with insulin therapies, contributing to overall improved health outcomes. Increased attention to healthcare in the public and private sectors is accelerating the integration of insulin into treatment plans for diabetes patients, particularly those with type 1 and type 2 diabetes, driving its growing adoption.

EUROPE HUMAN INSULIN MARKET ANALYSIS

In Europe, the growing adoption of human insulin is significantly driven by the expanding aging population. According to WHO, the aging population in the European Region is rapidly increasing, with the number of people aged 60 and older rising from 215 Million in 2021 to over 300 Million by 2050, offering a growing market for human insulin. As life expectancy increases, the elderly population is growing, which in turn is leading to higher incidences of chronic conditions such as diabetes. Older individuals are more prone to developing both type 1 and type 2 diabetes, creating a greater need for effective management solutions like insulin. Healthcare systems are responding to this demand by ensuring that insulin is more accessible to elderly patients, who often require long-term treatment. The focus on providing specialized care for older individuals, including those with diabetes, has contributed to the growing use of human insulin. The advent of more convenient advanced delivery devices, like insulin pens and pumps, for older patients further encourages the use of insulin. Additionally, public health initiatives aimed at addressing age-related chronic conditions have created a more favorable environment for insulin use. This combination of an aging demographic and healthcare sector adaptation is fueling the adoption of human insulin across European countries.

ASIA PACIFIC HUMAN INSULIN MARKET ANALYSIS

In the Asia-Pacific region, the rising adoption of human insulin can be attributed to the increasing prevalence of diabetes. According to reports, India, home to the world's second-highest number of diabetics, is projected to see a rise from 74.9 Million in 2021 to 124.9 Million by 2045, boosting demand for human insulin. With the rapid rise in lifestyle-related diseases, particularly diabetes, the demand for effective treatments like human insulin has surged. Rising healthcare awareness and the growing focus on diabetes management have led to greater accessibility to insulin therapy. Several countries in this region are witnessing a surge in diabetic populations due to dietary changes, sedentary lifestyles, and an aging population. In response, better access to insulin is being made possible by healthcare systems, which will improve diabetes control. Governments and healthcare providers are focusing on increasing awareness about diabetes prevention and management, thus contributing to higher adoption rates of human insulin. The financial strain that diabetes places on healthcare systems is also encouraging the adoption of insulin by promoting its wider availability. The increasing number of healthcare programs and initiatives designed to address the growing burden of diabetes has further facilitated the accessibility and use of insulin.

LATIN AMERICA HUMAN INSULIN MARKET ANALYSIS

The growing use of human insulin in Latin America is also influenced by the increasing availability of online retail pharmacy stores. For instance, the number of pharmacies in Latin America surged by 7% from 2020 to 2023, adding 14,598 new outlets, a sharp increase compared to the 18,858 stores added from 2010 to 2020. This rapid expansion, especially in online retail pharmacy stores, is improving accessibility to vital medications like human insulin, benefiting patients with easier access and convenience. As digital transformation spreads throughout the region, more individuals are turning to online platforms to access their healthcare needs, including medications such as insulin. Online pharmacies are making it simpler for patients to obtain insulin and have it supplied directly to their places, often at more lower costs. This shift towards e-commerce in healthcare is particularly important in regions where traditional pharmacy networks are less widespread. The convenience and affordability offered by online retail pharmacies are accelerating the adoption of insulin as patients are empowered to manage their diabetes more effectively. Moreover, these platforms often provide more flexible payment options, making insulin more accessible to a broader population.

MIDDLE EAST AND AFRICA HUMAN INSULIN MARKET ANALYSIS

In the Middle East and Africa, the growing adoption of human insulin is being propelled by the expansion of healthcare facilities. According to International Trade Administration, Saudi Arabia allocates 16.96% of its 2023 budget, or USD 50.4 Billion, to healthcare, accounting for 60% of the GCC's healthcare expenditure. This significant investment in healthcare facilities enhances access to critical treatments, including human insulin, benefiting the nation's health outcomes. As countries in this region focus on improving their healthcare infrastructure, there has been a significant increase in the number and quality of healthcare facilities offering diabetes care. With more clinics and hospitals equipped to diagnose and treat diabetes, there is greater availability of insulin for patients. Enhanced healthcare services are also enabling better diabetes management, contributing to the growing adoption of insulin therapies. As healthcare access improves, patients can receive timely insulin treatments, leading to better outcomes. The development of healthcare facilities across the region is playing a key role in increasing insulin adoption, especially as governments and organizations prioritize healthcare improvements to address the rising burden of diabetes. This development is revolutionizing access to healthcare by increasing the availability of insulin for individuals in need.

COMPETITIVE LANDSCAPE:

This global human insulin market is noted for competitive landscape, with the major players holding huge market shares and remains challenging for aspiring entrants. Increased incidences of diabetes have been fueling the demand for novel therapeutic insulin-delivery devices. Companies are working toward products' differentiation with the inventions of biosimilars and optimal formulations to serve better patient accessibility and treatment outcomes. For instance, according to industry reports, Novo Nordisk created Icodec, a weekly insulin approved by the European Medicines Agency (EMA) and nearing approval in India by the Subject Expert Committee (SEC), offering reduced injection frequency and improved compliance for individuals needing daily insulin therapy. In addition to this, collaborations and strategic alliances help an enterprise enter new markets.. Government regulations and reimbursement favorable policies, further boost increased market transformation as entry of new players into the field increases competition in the industry, thereby inciting innovations within the sector.

The report provides a comprehensive analysis of the competitive landscape in the human insulin market with detailed profiles of all major companies, including:

  • B. Braun Melsungen AG
  • Becton, Dickinson and Company (BD)
  • Biocon
  • Eli Lilly and Company
  • Gulf Pharmaceutical Industries (Julphar)
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Groupe Sanofi
  • SEDICO Co.
  • Wockhardt Limited
  • Ypsomed AG

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What is human insulin?

2. How big is the global human insulin market?

3. What is the expected growth rate of the global human insulin market during 2026-2034?

4. What are the key factors driving the global human insulin market?

5. What is the leading segment of the global human insulin market based on the product type?

6. What is the leading segment of the global human insulin market based on the distribution channel?

7. What is the leading segment of the global human insulin market based on the disease type?

8. What are the key regions in the global Human Insulin market?

9. Who are the key players/companies in the global Human Insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Breakup by Type
      • 6.1.2.1 Human Insulin Analogs and Biosimilars
        • 6.1.2.1.1 Rapid Acting
          • 6.1.2.1.1.1 Market Trends
          • 6.1.2.1.1.2 Market Forecast
        • 6.1.2.1.2 Long Acting
          • 6.1.2.1.2.1 Market Trends
          • 6.1.2.1.2.2 Market Forecast
        • 6.1.2.1.3 Premixed
          • 6.1.2.1.3.1 Market Trends
          • 6.1.2.1.3.2 Market Forecast
      • 6.1.2.2 Human Insulin Biologics
        • 6.1.2.2.1 Short Acting
          • 6.1.2.2.1.1 Market Trends
          • 6.1.2.2.1.2 Market Forecast
        • 6.1.2.2.2 Intermediate Acting
          • 6.1.2.2.2.1 Market Trends
          • 6.1.2.2.2.2 Market Forecast
        • 6.1.2.2.3 Premixed
          • 6.1.2.2.3.1 Market Trends
          • 6.1.2.2.3.2 Market Forecast
    • 6.1.3 Market Forecast
  • 6.2 Delivery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Breakup by Type
      • 6.2.2.1 Pens
        • 6.2.2.1.1 Reusable Pens
        • 6.2.2.1.2 Disposable Pens
      • 6.2.2.2 Pen Needles
        • 6.2.2.2.1 Standard Pen Needles
        • 6.2.2.2.2 Safety Pen Needles
      • 6.2.2.3 Syringes
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Retail Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Hospital Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Retail Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Type I Diabetes
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type II Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 B. Braun Melsungen AG
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Becton, Dickinson and Company (BD)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biocon
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Gulf Pharmaceutical Industries (Julphar)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novo Nordisk A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Groupe Sanofi
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SEDICO Co.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Wockhardt Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 Ypsomed AG
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Human Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Insulin Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Human Insulin Market: Breakup by Product Type (in %), 2025
  • Figure 4: Global: Human Insulin Drugs Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Human Insulin Delivery Devices Market: Breakup by Type (in %), 2025
  • Figure 6: Global: Human Insulin Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Human Insulin Market: Breakup by Disease Type (in %), 2025
  • Figure 8: Global: Human Insulin Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Human Insulin Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 10: Global: Human Insulin (Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Human Insulin Drugs (Analogs and Biosimilars) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Human Insulin Drugs (Analogs and Biosimilars- Rapid Acting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Human Insulin Drugs (Analogs and Biosimilars- Long Acting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Human Insulin Drugs (Analogs and Biosimilars- Premixed) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Human Insulin Drugs (Analogs and Biosimilars) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Human Insulin Drugs (Biologics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Human Insulin Drugs (Biologics - Short Acting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Human Insulin Drugs (Biologics - Short Acting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Human Insulin Drugs (Biologics - Intermediate Acting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Human Insulin Drugs (Biologics - Premixed) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Human Insulin Drugs (Biologics - Premixed) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Human Insulin Drugs (Biologics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Human Insulin (Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Human Insulin (Delivery Devices) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Human Insulin Delivery Devices (Pens) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Human Insulin Delivery Devices (Pens) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Human Insulin Delivery Devices (Pen Needles) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Human Insulin Delivery Devices (Pen Needles) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Human Insulin Delivery Devices (Syringes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Human Insulin Delivery Devices (Syringes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Human Insulin Delivery Devices (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Human Insulin Delivery Devices (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Human Insulin (Delivery Devices) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Human Insulin Market: Sales through Retail Pharmacies (in Million USD), 2020 & 2025
  • Figure 39: Global: Human Insulin Market Forecast: Sales through Retail Pharmacies (in Million USD), 2026-2034
  • Figure 40: Global: Human Insulin Market: Sales through Hospital Pharmacies (in Million USD), 2020 & 2025
  • Figure 41: Global: Human Insulin Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2026-2034
  • Figure 42: Global: Human Insulin Market: Sales through Online Retail Stores (in Million USD), 2020 & 2025
  • Figure 43: Global: Human Insulin Market Forecast: Sales through Online Retail Stores (in Million USD), 2026-2034
  • Figure 44: Global: Human Insulin Market: Sales through Other Distribution Channels (in Million USD), 2020 & 2025
  • Figure 45: Global: Human Insulin Market Forecast: Sales through Other Distribution Channels (in Million USD), 2026-2034
  • Figure 46: Global: Human Insulin (Type I Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Human Insulin (Type I Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Human Insulin (Type II Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Global: Human Insulin (Type II Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: North America: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: North America: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: United States: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: United States: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Canada: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Canada: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Asia Pacific: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Asia Pacific: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: China: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: China: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Japan: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Japan: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: India: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: India: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: South Korea: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: South Korea: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Australia: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Australia: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Indonesia: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Indonesia: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Others: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Others: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Europe: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Europe: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Germany: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Germany: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: France: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: France: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: United Kingdom: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: United Kingdom: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Italy: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Italy: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Spain: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Spain: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Russia: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Russia: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Others: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Others: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Latin America: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Latin America: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Brazil: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Brazil: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Mexico: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Mexico: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Others: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 95: Others: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Middle East and Africa: Human Insulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 97: Middle East and Africa: Human Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 98: Global: Human Insulin Industry: SWOT Analysis
  • Figure 99: Global: Human Insulin Industry: Value Chain Analysis
  • Figure 100: Global: Human Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Insulin Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Human Insulin Market Forecast: Breakup by Product Type (in Million USD), 2026-2034
  • Table 3: Global: Human Insulin Drugs Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 4: Global: Human Insulin Delivery Devices Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 5: Global: Human Insulin Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Human Insulin Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 7: Global: Human Insulin Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Human Insulin Market: Competitive Structure
  • Table 9: Global: Human Insulin Market: Key Players